Correction: Cellular hierarchy framework based on single-cell/multi-patient sample sequencing reveals metabolic biomarker PYGL as a therapeutic target for HNSCC
Jiezhong Guan, Xi Xu, Guo Qiu, Chong He, Xiaoyue Lu, Kang Wang, Xinyu Liu, Yuanyuan Li, Zihang Ling, Xuan Tang, Yujie Liang, Xiaoan Tao, Bin Cheng, Bo Yang
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsCancer, Hypoxia, and Metabolism · Cancer, Lipids, and Metabolism · Ferroptosis and cancer prognosis
Correction: J Exp Clin Cancer Res 42, 162 (2023)
https://doi.org/10.1186/s13046-023-02734-w
Following the publication of the original article [1], the authors identified error in Fig. 5F where the metastatic nodules in mice after PYGL-KD and cisplatin therapy, was mistakenly displayed.
The correct figure is presented below:
**Incorrect **Fig. 5fFig.5Chemotherapy resistance and metastasis of HNSCC promoted by PYGL. A Prediction of cisplatin IC50 in METArisk-high and METArisk-low groups. B Prediction of cisplatin IC50 in high and low PYGL expression groups. C Computational analysis of resistance with PYGL of cisplatin in the CARE database. D Tumor growth was measured once a week in tumor-bearing nude mice stably transfected with HNSCC cells (n = 5). E The tumors were removed, and the tumor weight was analyzed after the mice were executed. F Metastasis of HNSCC was measured by the results of hematoxylin–eosin staining of mice lung tissue
**Correct **Fig. 5fFig.5Chemotherapy resistance and metastasis of HNSCC promoted by PYGL. A Prediction of cisplatin IC50 in METArisk-high and METArisk-low groups. B Prediction of cisplatin IC50 in high and low PYGL expression groups. C Computational analysis of resistance with PYGL of cisplatin in the CARE database. D Tumor growth was measured once a week in tumor-bearing nude mice stably transfected with HNSCC cells (n = 5). E The tumors were removed, and the tumor weight was analyzed after the mice were executed. F Metastasis of HNSCC was measured by the results of hematoxylin–eosin staining of mice lung tissue
The correction does not compromise the validity of the conclusions and the overall content of the article. The original article [1] has been updated.